Global BRAF Kinase Inhibitor Market Companies
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bayer AG
- Boehringer Ingelheim International
- Bristol-Myers Squibb Company
- Eisai Co. Ltd
- Johnson and Johnson
- Pfizer Inc.
- Eli Lilly and Company
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Spectrum Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
Recent News:
- In August 2022, Theseus Pharmaceuticals, Inc. announced business and pipeline highlights focused on developing next-generation tyrosine kinase inhibitors (TKIs) to suppress cancer resistance.
- In August 2022, the FDA granted permanent approval to the tyrosine kinase inhibitor capmatinib for metastatic non-small cell lung cancer (NSCLC) patients whose tumors have mutations leading to exon 14 skipping. MET.
- In June 2022, the European Commission approved capmatinib (Tablecta), a tyrosine kinase inhibitor, as a single agent for the treatment of patients with advanced non-small cell lung cancer. Mutation (NSCLC) requires systemic treatment. Treatment after previous treatment with immunotherapy and/or platinum-based chemotherapy. In February 2022, Merck announced that the European Commission (EC) approved TEPMETKO (tepotinib), a once-daily oral tyrosine kinase inhibitor, as immunotherapy for the treatment of patient’s adults with advanced non-inflammatory lung cancer (NSCLC). .
- In March 2021, Pfizer Inc. received US FDA approval for a supplemental new drug application (sNDA) for LORBRENA (lorlatinib), a tyrosine kinase inhibitor, expanding the indication to include the first-line treatment of with anaplastic lymphoma kinase (ALK). - Positive non-small cell lung cancer (NSCLC). LORBRENA is indicated in adults with metastatic NSCLC whose ALK-positive tumors are detected by an FDA-approved test.